Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Common Equity (2016 - 2025)

Historic Common Equity for United Therapeutics (UTHR) over the last 17 years, with Q3 2025 value amounting to $6.6 billion.

  • United Therapeutics' Common Equity rose 802.01% to $6.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $6.6 billion, marking a year-over-year increase of 802.01%. This contributed to the annual value of $6.4 billion for FY2024, which is 767.28% up from last year.
  • Latest data reveals that United Therapeutics reported Common Equity of $6.6 billion as of Q3 2025, which was up 802.01% from $7.2 billion recorded in Q2 2025.
  • In the past 5 years, United Therapeutics' Common Equity registered a high of $7.2 billion during Q2 2025, and its lowest value of $3.4 billion during Q1 2021.
  • Over the past 5 years, United Therapeutics' median Common Equity value was $5.3 billion (recorded in 2024), while the average stood at $5.2 billion.
  • As far as peak fluctuations go, United Therapeutics' Common Equity skyrocketed by 419.46% in 2024, and later surged by 2752.1% in 2025.
  • Over the past 5 years, United Therapeutics' Common Equity (Quarter) stood at $4.0 billion in 2021, then increased by 21.16% to $4.8 billion in 2022, then grew by 24.77% to $6.0 billion in 2023, then increased by 7.67% to $6.4 billion in 2024, then increased by 2.27% to $6.6 billion in 2025.
  • Its last three reported values are $6.6 billion in Q3 2025, $7.2 billion for Q2 2025, and $6.8 billion during Q1 2025.